Subject: Specialty Quantity Limit Balversa 2968-H P2023
Policy:
I. PROGRAM DESCRIPTION
The standard limit is designed to allow a quantity sufficient for
the most common uses of the medication. The recommended
dosing parameters for all FDA-approved indications fall within
the standard limits. Coverage of an additional quantity may be
reviewed on a case-by-case basis upon request.
II. COVERED QUANTITIES
|
Medication
|
Standard Limit
|
FDA-recommended dosing
|
|
Balversa (erdafitinib)
3 mg
|
84 per 28 days
|
The recommended starting dose is 8 mg (two 4 mg tablets) once daily, with a dose increase to 9 mg (three 3 mg tablets) once daily based on serum phosphate levels and tolerability at 14 to 21 days.
The following dose adjustments may be necessary:
- 8 mg (two 4 mg tablets) daily
- 6 mg (two 3 mg tablets) daily
- 5 mg (one 5 mg tablet) daily
- 4 mg (one 4 mg tablet) daily
|
|
Balversa (erdafitinib)
4 mg
|
56 per 28 days
|
|
Balversa (erdafitinib)
5 mg
|
28 per 28 days
|
Place of Service:
Outpatient
The above policy is based on the following references:
1. Balversa [package insert]. Horsham, PA: Janssen Products, LP;
January 2023.
Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.
December 31, 2023
